MedPath

Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF

Phase 4
Conditions
Infertility
Interventions
Registration Number
NCT02690870
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Brief Summary

The purpose of this prospective cohort study is to compare IVF outcome between tamoxifen and clomiphene citrate in mild stimulation.

Detailed Description

The reported prevalence of poor ovarian responders amongst patients undergoing IVF-ET is 9%-24%, and morbidity must be higher nowadays. For these women, Mild stimulation has been an important ovulation induction protocol. Clomiphene citrate(CC) and tamoxifen(TMX) are commonly used in mild stimulation protocol. It's reported that CC has adverse effect on growth of endrometrium and results in thin endrometrium(≤7mm) which maybe affect pregnancy rate. However, TMX has estrogen-like effect on the endrometrium that may be helpful to increase endormetrial thickness. The reported results about comparing CC with TMX showed that they had similar ovulation rate. Prospective study is necessary to confirm whether TMX is superior to CC on the IVF outcome.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
210
Inclusion Criteria
  1. age between 37 and 42;
  2. BMI≤23kg/m2;
  3. ≤3 oocytes with a conventional stimulation protocol;
  4. AFC<5 follicles or AMH<1.1 ng/ml on the day 1 to 5 of the menses;
  5. Cause of Infertiity: tubal factor, male factor, diminished ovarian reserve.
Exclusion Criteria
  1. endormetrial polyp, endormetrial cancer,intrauterine adhesions,uterine fibroids that affects uterine cavity
  2. Endometriosis, adenomyosis
  3. The diameter of Hydrosalpinx >2cm

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
tamoxifenTamoxifenAll patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses(D3).Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from D3 for 5 days.All patients will check serum E2 and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle. The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG administration. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
clomipheneClomipheneAll patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses(D3).Patients in clomiphene group will take 100 mg of CC oral tablets daily from D3 for 5 days.All patients will have sexual hormone determination and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle.The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG injection. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
Primary Outcome Measures
NameTimeMethod
clinical pregnancy ratefour weeks after embryo transfer
Secondary Outcome Measures
NameTimeMethod
endrometrial pattern and thickness on the day of HCG administrationon the HCG day
cycle cancellations for thin endrometrial thicknesson the HCG day
the number of follicular diameter≥10mm and sexual hormone test on the HCG dayon the HCG day
© Copyright 2025. All Rights Reserved by MedPath